Analyzing KalVista Pharmaceuticals (KALV) and The Competition
KalVista Pharmaceuticals (NASDAQ: KALV) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it compare to its rivals? We will compare KalVista Pharmaceuticals to similar businesses based on the strength of its risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
Volatility & Risk
KalVista Pharmaceuticals has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals’ rivals have a beta of 1.12, meaning that their average share price is 12% more volatile than the S&P 500.
Earnings & Valuation
This table compares KalVista Pharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$1.50 million||-$18.60 million||N/A|
|KalVista Pharmaceuticals Competitors||$564.12 million||$96.17 million||44.04|
KalVista Pharmaceuticals’ rivals have higher revenue and earnings than KalVista Pharmaceuticals.
Institutional and Insider Ownership
76.1% of KalVista Pharmaceuticals shares are held by institutional investors. Comparatively, 43.5% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 49.1% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 15.3% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares KalVista Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|KalVista Pharmaceuticals Competitors||-13,604.44%||-110.52%||-27.86%|
This is a summary of current ratings and target prices for KalVista Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|KalVista Pharmaceuticals Competitors||139||801||1770||60||2.63|
KalVista Pharmaceuticals currently has a consensus price target of $27.00, indicating a potential upside of 183.91%. As a group, “Biopharmaceuticals” companies have a potential upside of 11.22%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe KalVista Pharmaceuticals is more favorable than its rivals.
KalVista Pharmaceuticals beats its rivals on 8 of the 12 factors compared.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.